Indegene, a commercialization company of Bangalore-based life sciences company, believes that despite uncertainty about the new Trump regime’s stance on regulatory and pricing issues, the largest U.S. market has grown important growth space. CEO and co-founder Manish Gupta told top pharmaceutical companies around the world are using technology and AI to make the process more agile, which will improve Indegene’s advantages. Mint In the interview.
“The fact that the aging population, rising incomes and technology is in a stage where multiple options can be invested in, [means] “This industry will continue to grow for a long time,” Gupta said.
A large portion of Indegene’s revenue (as of 3FY25 Q3FY25) comes from the top 20 pharmaceutical companies around the world. Most of them are located in the United States and Europe, accounting for more than 95% of the company’s business.
Read more: Trump’s spending on suspension of inflation reduction bill has no negative impact: Waaree’s Amit Paintankar
In addition to leveraging its AI expertise to grow in the U.S., Indegene has also expanded its footprint in Europe, with many investments and centers over the past few months.
Indegene provides commercial services to large pharmaceutical companies to promote and sell their products as well as back-end operations such as regulatory submissions and data management.
Our tail wind
The Biden administration’s inflation reduction bill in 2022 focuses on reducing prescription drugs costs and increasing pricing pressure on U.S. biopharmaceutical companies. The current government has not yet taken a stance on this, but the industry is closely monitoring it.
“We have a practical practice that revolves around the U.S. price and market access … This is a very important area for us and pharmaceutical companies. Our practice is closely watching,” Gupta said.
“For the past 25 years, we have been in business and we have been hearing news about the pressure on drug pricing … we believe that this pressure will remain in this industry.”
Pricing pressures and increased regulatory complexity are leading to more businesses using technology and outsourcing processes. We believe that in the United States and other parts of the world, government policies, competitive momentum, and the technological landscape of development will force Biopharma to reimagine how they can commercialize and develop. This will provide a lot of motivation for digital-first services companies like Indegene.
Gupta told Mint This kind of India has been incorporating artificial intelligence into its products over the past decade. “We do use AI-based tools, and we’ve been using some of the AI tools we’ve made to deliver very different results to the industry,” he said.
Read more: Wipro GE Healthcare launches $1 billion expansion plan to boost domestic manufacturing
Earlier this year, the company launched Cortex, an AI-based generation platform, an extension of its AI products.
A strong drug pipeline is expected to contribute to growth in the next 3-4 years.
European expansion
The company has expanded its expansion in Europe over the past few months. Currently, it has 27% of its business from the region.
Earlier this month, it opened a new centre in London. The company also announced the acquisition of medical communications company MJL Communications Group Ltd through its subsidiary Indegene Indegene Indegene. In February, it launched a new entity in Spain as part of its strategic expansion.
“Among the top 20 pharmaceutical companies in Europe, many of them already exist in the European stage, and this will be an important market,” Gupta said.
Listed on the stock exchange last year. Gupta says the company’s revenue is from ₹330 million in 2010 ₹In 2024, US$25 billion. While he refused to share recent guidance, Gupta said he hopes the company will multiply over the next five to seven years.
